TRCT
DMAQR

Tower Research Capital (TRC)’s Deep Medicine Acquisition Corp. Rights DMAQR Stock Holding History

Tower Research Capital (TRC)’s Portfolio DMAQR Stock Details DMAQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-9,792
Closed -$2K – 6729
2022
Q1 		$2K Hold
9,792
– – ﹤0.01% 5649
2021
Q4 		$3K Buy
+9,792
New +$3.1K ﹤0.01% 5526

Other funds holding DMAQR

CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Tower Research Capital (TRC)'s DMAQR Position: Q2 2022 in Review

Tower Research Capital (TRC) sold out of Deep Medicine Acquisition Corp. Rights (DMAQR) in Q2 2022, closing a stake of 9,792 shares — an estimated $2K sold.

Tower Research Capital (TRC) first reported a position in DMAQR in Q4 2021 and held it in 2 quarters. The position peaked at $3K in Q4 2021. 31 funds tracked by Wall St. Rank hold DMAQR as of Q2 2022.

  • Tower Research Capital (TRC) reported no remaining Deep Medicine Acquisition Corp. Rights position as of Q2 2022 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 9,792 Deep Medicine Acquisition Corp. Rights shares in Q2 2022, an estimated $2K.
  • Tower Research Capital (TRC) first reported a position in Deep Medicine Acquisition Corp. Rights in Q4 2021 and held it in 2 quarters.
  • Tower Research Capital (TRC)'s Deep Medicine Acquisition Corp. Rights position peaked at $3K in Q4 2021.
  • 31 funds tracked by Wall St. Rank held Deep Medicine Acquisition Corp. Rights as of Q2 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2022, filed 15 Aug 2022.